Arthneeti
Latest: Nureca Q2 FY27 results →All Q1 FY27 results →
N

Nureca

Q1 FY27

Nureca Q1 FY27: Revenue ₹40.3 Cr, PAT ₹3.1 Cr

Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.

Price₹320
Market cap₹305 Cr
P/E70.3
Updated16 Oct 2026
Read3 min read

Based on Nureca's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

The short version

Revenue from Operations for Q1 FY'27: ₹40.3 Cr - Up 18% YoY (Q1 FY'26: ₹34.2 Cr) - Up 14% QoQ (Q4 FY'26: ₹35.4 Cr) - Gross Merchandise Value (GMV) in Q1 FY'27: ₹51.8 Cr - Q4 FY'26 GMV: ₹4 EBITDA (Q1 FY27): ₹5.2 Cr, up 160% YoY (from ₹2.0 Cr in Q1 FY26) - Operating Margin (Q1 FY27): 8.7%, increased by 10.4 percentage points YoY (from -1.8% in Q1 FY26) - PAT (Q1 FY27): ₹3.1

From Nureca's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

  • Revenue from Operations for Q1 FY'27: ₹40.3 Cr
  • Up 18% YoY (Q1 FY'26: ₹34.2 Cr)
  • Up 14% QoQ (Q4 FY'26: ₹35.4 Cr)
  • Gross Merchandise Value (GMV) in Q1 FY'27: ₹51.8 Cr
  • Q4 FY'26 GMV: ₹49.7 Cr
  • Operating Profit: ₹3.4 Cr (8.7% margin) in Q1 FY'27 vs ₹0.9 Cr (2.4%) YoY
  • EBITDA: ₹5.2 Cr (12%) in Q1 FY'27 vs ₹2.0 Cr (5%) YoY

2 more points from Nureca's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Nureca said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Construction begins for new medical device facility at Sundran, Punjab (2026).
  • USFDA registration completed for Mohali manufacturing facility (2025).
  • Existing NTPL Mohali plant has annual capacity of 8 lakh units, manufactures BP monitors, nebulizers, thermometers, massagers, and other products.
  • Manufacturing expansion in Punjab aims to deepen supply-chain control, promote import substitution, and open new opportunities in medical devices, consumables, and hygiene.

2 more points from Nureca's call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Nureca said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Nureca said on order book & pipeline — free account, 30 seconds.

Nureca — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹59 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Nureca Ltd's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

  • Avience Biomedicals Ltd (Q1 FY27)

    New manufacturing facility has capacity to support peak revenue of around ₹250–265 crore, subject to product mix and approvals. Key concall takeaways from…

  • Fischer Medical Ventures Ltd (Q1 FY27)

    The provided pages of the investor presentation do not contain any specific revenue, sales, or volume figures for the quarter, nor details on year-on-year…

  • Molbio Diagnosti (Q1 FY27)

    Capacity utilization currently at ~58% for test kits and ~42% for devices; automation capex will double revenue capacity with minimal new investment. Key…

  • QMS Medical Allied Services Ltd (Q1 FY27)

    Contract renewals historically exhibit a 60-70% roll-over rate annually, ensuring revenue visibility from existing clients. Key concall takeaways from QMS…

Compare:vs Poly Medicure Ltdvs Molbio Diagnostivs Sahajanand Medical Technologies Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Nureca and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Nureca Q1 FY27 results?

Revenue from Operations for Q1 FY'27: ₹40.3 Cr - Up 18% YoY (Q1 FY'26: ₹34.2 Cr) - Up 14% QoQ (Q4 FY'26: ₹35.4 Cr) - Gross Merchandise Value (GMV) in Q1 FY'27: ₹51.8 Cr - Q4 FY'26 GMV: ₹4 EBITDA (Q1 FY27): ₹5.2 Cr, up 160% YoY (from ₹2.0 Cr in Q1 FY26) - Operating Margin (Q1 FY27): 8.7%, increased by 10.4 percentage points YoY (from -1.8% in Q1 FY26) - PAT (Q1 FY27): ₹3.1

What is Nureca share price analysis?

Nureca currently shows a neutral. The stock trades at a P/E of 70.3 with a market cap of ₹305 Cr. Investors should review the full earnings analysis for detailed insights.

Is Nureca planning capital expenditure?

Construction begins for new medical device facility at Sundran, Punjab (2026).

Keep Nureca on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.